2 completed, 1 recruiting. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
Follow SCCHN: new trials by email Literature Review of SCCHN trials Research Report on SCCHN
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection), Pembrolizumab (KEYTRUDA®), VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection) - Head and Neck Cancers- Squamous Cell, Head and Neck Cancer | Phase 1 | Recruiting | VLP Therapeutics | 41 | 2025-05-13 | 2026-09-21 |
| Study of XB002 in Subjects With Solid Tumors (JEWEL-101) XB002, Nivolumab, Bevacizumab - Non Small Cell Lung Cancer, Cervical Cancer | Phase 1 | Completed | Exelixis | 269 | 2021-06-07 | 2025-04-04 |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors PF-06801591 - Part 1, MELANOMA | Phase 1 | Completed | Pfizer | 147 | 2016-02-10 | 2021-12-13 |
Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Melanoma (1) · Mouth Neoplasms (1) · Pancreatic Neoplasms (1) · Sarcoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
Carcinoma (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Neoplasms, Squamous Cell (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Adnexal Diseases (1) · Breast Diseases (1) · Breast Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1) · Digestive System Diseases (1)
Bevacizumab (1) · Nivolumab (1) · pembrolizumab (1)
Exelixis (1) · Pfizer (1) · VLP Therapeutics (1)
United States (3) · South Korea (2) · Australia (1) · Belgium (1) · Bulgaria (1) · France (1) · Italy (1) · Malaysia (1) · Netherlands (1) · Poland (1) · Russia (1) · Spain (1) · Ukraine (1) · United Kingdom (1)
Fred M Baik, MD (1)
PMID 31145415, PMID 34694529, PMID 39671539
2016 (1)